Aspirin in type 2 diabetes, a randomised controlled study: effect of different doses on inflammation, oxidative stress, insulin resistance and endothelial function.

No Thumbnail Available
Authors
Raghavan, R P
Laight, D W
Cummings, M H
Issue Date
2014-02-01
Journal
Type
Peer-Reviewed Publication
Randomised Control Trial
Keywords
Adult
Aged
Biomarkers
Blood glucose
Type 2 diabetes mellitus
Diabetes mellitus
Diabetic angiopathies
Drug dose-response relationship
Vascular endothelium
Glutathione
Hypoglycemic agents
Insulin resistance
Middle aged
Oxidative stress
Vasculitis
Aspirin
Journal Title
International Journal of Clinical Practice
Volume
68
Issue
2
Begin page
271
End page
277
Abstract
Objectives The effect of aspirin upon platelet function is well documented although experimental studies suggest that aspirin may also affect oxidative stress, vascular inflammation, endothelial dysfunction and dysglycaemia. The optimal dose of aspirin for cardiovascular protection in type 2 diabetes is still debated. We examined the effects of different doses of aspirin upon these novel markers of cardiovascular risk and any association between aspirin-mediated changes in these markers. Methodology Subjects with type 2 diabetes attended for baseline evaluation including BMI, glycaemic and lipid markers, endothelial function (photoplethysmography), insulin resistance (HOMA), inflammation (sVCAM-1 and Hs-CRP) and markers of oxidative stress [total anti-oxidant status (TAOS and FRAP), whole blood total glutathione (GSH) assays]. Subjects then received in random, sequential, blinded fashion aspirin 75 mg day−1, aspirin 300 mg day−1, aspirin 3.6 g day−1 or placebo for 2 weeks with a 2-week washout. The above investigations were repeated after each intervention. Aspirin-related changes compared with placebo were analysed using repeated measures ANOVA. Results Subjects = 17 (M – 12; F – 5), mean age – 57.4 ± 9.1 years (mean ± 1 SD), HbA1c – 63 ± 13 mmol mol−1 (7.9 ± 1.2%), total cholesterol 4.57 ± 1.01 mmol l−1. At baseline TAOS value was 59.3 ± 9.7 μM AEAC (Ascorbate Equivalent Anti-oxidant Concentration), glutathione 302.2 ± 183.3 mmol l−1 and FRAP 0.86 ± 0.23 mM FeII. None of the aspirin doses had a significant impact upon BMI, blood pressure, lipid parameters, insulin sensitivity (HOMA), FRAP, TAOS, GSH, endothelial function, glycaemic control (fructosamine) or inflammation (sVCAM-1 and HsCRP).
Citation
Raghavan RP, Laight DW, Cummings MH. Aspirin in type 2 diabetes, a randomised controlled study: effect of different doses on inflammation, oxidative stress, insulin resistance and endothelial function. Int J Clin Pract. 2014 Feb;68(2):271-7. doi: 10.1111/ijcp.12310. Epub 2013 Dec 22. PMID: 24372992.